Media coverage about Applied Genetic Technologies Corporation (NASDAQ:AGTC) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Applied Genetic Technologies Corporation earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.8021797595991 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

AGTC has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Applied Genetic Technologies Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. ValuEngine lowered shares of Applied Genetic Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. HC Wainwright set a $16.00 target price on shares of Applied Genetic Technologies Corporation and gave the stock a “buy” rating in a research report on Thursday, August 10th. Stifel Nicolaus decreased their target price on shares of Applied Genetic Technologies Corporation from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, May 11th. Finally, Cantor Fitzgerald set a $15.00 target price on shares of Applied Genetic Technologies Corporation and gave the stock a “hold” rating in a research report on Wednesday, May 10th. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Applied Genetic Technologies Corporation currently has an average rating of “Buy” and an average price target of $13.81.

Shares of Applied Genetic Technologies Corporation (NASDAQ:AGTC) traded down 1.09% during mid-day trading on Friday, hitting $4.55. 119,581 shares of the stock were exchanged. The stock’s 50-day moving average is $4.85 and its 200-day moving average is $5.88. Applied Genetic Technologies Corporation has a 52 week low of $4.50 and a 52 week high of $13.36. The stock has a market capitalization of $82.25 million, a price-to-earnings ratio of 10.86 and a beta of 1.68.

TRADEMARK VIOLATION NOTICE: “Applied Genetic Technologies Corporation (AGTC) Earns Media Sentiment Score of 0.11” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/26/applied-genetic-technologies-corporation-agtc-earns-media-sentiment-score-of-0-11.html.

About Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Insider Buying and Selling by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Stock Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related stocks with our FREE daily email newsletter.